Skip to main content
Premium Trial:

Request an Annual Quote

David Owen, Thomas Joos, Forest White, and Affymetrix


People in the News

Oxford Gene Technology has named David Owen non-executive director, the company said this week.

Owen is currently non-executive chairman of Abcellute and the Cardiff Partnership Fund, co-chairman of EMBL Enterprise Management and is a past president of the Association of European Science and Technology Transfer Professionals.

Owen holds a PhD in pharmacology and has worked in the past for SmithKline & French, now GlaxoSmithKline.

Epitome Biosystems said this week that it has added Thomas Joos and Forest White to its scientific advisory board.

Joos is the head of the biochemistry department at the Natural and Medical Sciences Institute at the University of Tuebingen. Prior to joining NMI in 1998, Joos was a researcher at the Max Planck Institute of Developmental Biology. Joos received a PhD in biochemistry from the University of Tuebingen in 1995.

Forest White is an assistant professor in the division of biological engineering at the Massachusetts Institute of Technology. He holds a PhD in analytical chemistry from Florida State University.


New Product Watch

Affymetrix last week launched three new products: its Human Exon 1.0 ST Array, its GeneChip Mapping 500K Set arrays for SNP genotyping, and its GeneChip Array Station for high-throughput experiments.

The Human Exon 1.0 ST Array offers whole-genome, exon-level expression profiling on one array, giving researchers the opportunity to examine approximately one million exons, Affy said. Affy said that the Human Exon 1.0 also enables users to study splicing events and discover novel splice variants.

The company's accompanying Exon Array System comes with the array, optimized reagents, Affy's Exon Array Computational Tool for detection and signal estimation and access to the NetAffx Analysis Center and the Integrated Genome Browser for analysis and array design information and annotation.

The GeneChip Mapping 500K Array Set is made up of two arrays, each capable of genotyping on average 250,000 SNPs for whole-genome associational studies. It is optimized to run with several of the company's assays, including the ParAllele Assay, and works on Affy's standard platform of the GC Scanner 3000 7G, Hybridization Oven 640, Fluidics Station 450, and GC Genotyping Analysis Software and Operating Software.

Finally, the GeneChip Array Station is designed for high-throughput microarray experiments.

The Array Station was co-developed with Caliper Life Sciences and features an upgraded Caliper SciClone liquid-handling workstation and an on-board Twister II plate handler,GeneChip microarrays, optimized assays and reagents, as well as open software architecture.

Affy said it will add high-throughput array plates that will offer GeneChip arrays in a 96-well format later in the year.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.